Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Soleno Therapeutics Inc. diskutieren

Soleno Therapeutics Inc.

WKN: A3DS0P / Symbol: SLNO / Name: Soleno Therapeutics / Aktie / Micro Cap /

41,30 €
-1,43 %

Einschätzung Buy
Rendite (%) -14,80 %
Kursziel 70,68
Veränderung
Endet am 02.12.25

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $74.00 price target on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,88 %
Kursziel 66,82
Veränderung
Endet am 03.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,19 %
Kursziel 68,86
Veränderung
Endet am 05.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $74.00 price target on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -30,78 %
Kursziel 114,25
Veränderung
Endet am 27.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Cantor Fitzgerald from $67.00 to $123.00. They now have an "overweight" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -30,78 %
Kursziel 94,75
Veränderung
Endet am 27.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Robert W. Baird from $72.00 to $102.00. They now have an "outperform" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -28,14 %
Kursziel 97,53
Veränderung
Endet am 27.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Laidlaw from $75.00 to $105.00. They now have a "buy" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -32,78 %
Kursziel 100,04
Veränderung
Endet am 28.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Stifel Nicolaus from $74.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -31,74 %
Kursziel 92,24
Veränderung
Endet am 31.03.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at HC Wainwright from $70.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -28,89 %
Kursziel 88,31
Veränderung
Endet am 15.04.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -34,96 %
Kursziel 127,70
Veränderung
Endet am 24.04.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Piper Sandler from $93.00 to $145.00. They now have an "overweight" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -37,03 %
Kursziel 92,69
Veränderung
Endet am 08.05.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Robert W. Baird from $102.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -34,76 %
Kursziel 85,63
Veränderung
Endet am 08.05.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Guggenheim from $81.00 to $97.00. They now have a "buy" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -33,24 %
Kursziel 95,67
Veränderung
Endet am 23.06.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at TD Cowen. They set a "buy" rating and a $110.00 price target on the stock.
Ratings data for SLNO provided by MarketBeat

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -32,74 %
Kursziel 103,64
Veränderung
Endet am 11.07.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Robert W. Baird from $105.00 to $121.00. They now have an "outperform" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -35,94 %
Kursziel 94,33
Veränderung
Endet am 07.08.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $105.00 to $110.00. They now have an "outperform" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -35,94 %
Kursziel 90,90
Veränderung
Endet am 07.08.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Guggenheim from $97.00 to $106.00. They now have a "buy" rating on the stock.
Ratings data for SLNO provided by MarketBeat

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Ratings data for SLNO provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,73 %
Kursziel 94,00
Veränderung
Endet am 18.08.26

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock, up previously from $100.00.
Ratings data for SLNO provided by MarketBeat